Citations

Showing 10 of 108094 citations.

Postpartum Contraception use in Somali Women: A Population-Based Study [5F]
Weaver, Amy L. , Casey, Petra M., Cope, Adela G. , Mara, Kristin C.

Mayo Clinic

Obstetrics & Gynecology | April 27, 2018 | Volume: 131 | Issue: 1 | Pages: 64S-64S

10.1097/01.aog.0000533315.94431.fd Get It

INTRODUCTION: Contraception is an important resource for Somali women as this population is at increased risk for adverse pregnancy outcomes. This study compares postpartum contraception use between Somali and non-Somali women. METHODS: A retrospective cohort study was performed utilizing the Rochester Epidemiology Project. All Somali women aged 18 and older who experienced liveborn, singleton births in Olmsted County, Minnesota, in 2009-2015 (n=317) and an age-matched non-Somali cohort (n=317) were identified. Postpartum contraception was defined as use of any method within 12 months after the first delivery in the time period of interest. Contraception use was compared using a chi-square test. Factors associated with contraception use were evaluated using multivariable logistic regression. RESULTS: Somali women were significantly less likely to use contraception than non-Somali women (62.1% versus 89.3%, p<0.001). Of those who used contraception, both Somali and non-Somali women reported comparable use of long-acting reversible contraception (LARC) (19.8% versus 23.7%, p=0.31) and non-LARC hormonal contraception (40.1% versus 45.2%, p=0.26). Somali women were more likely to use less reliable methods including natural family planning and barrier methods (57.3% versus 21.1%, p<0.001). Among Somali women, postpartum contraception use was less likely with older maternal age (OR 0.12 for oldest versus youngest quartile, 95% CI 0.04-0.37) and more likely with pre-pregnancy contraception use (OR 15.46, 95% CI 5.18-46.18). CONCLUSION: Our study represents the first assessment in the literature of contraception use in Somali women in the United States. Somali women are less likely to utilize postpartum contraception, highlighting an opportunity for improvement in counseling practices.
The Prevalence of Postnatal Depression in Women with a History of Bariatric Surgery [33R]
Kok, Susan N., Kim, Sharon J. , Grothe, Karen, Moore, Katherine M. , Long, Margaret E. , Collazo–Clavell, Maria L.

Mayo Clinic

Obstetrics & Gynecology | April 27, 2018 | Volume: 131 | Issue: 1 | Pages: 203S-203S

10.1097/01.aog.0000533284.01163.74 Get It

INTRODUCTION: Obesity is associated with postnatal depression; however, the prevalence of postnatal depression in women after bariatric surgery has not been further evaluated. METHODS: For this observational investigation, women, ages 18-45 years, with pregnancy from 1989-2015 and bariatric surgery were identified using the Olmsted County Rochester Epidemiology Project and ICD-9 codes. Those with surgery after pregnancy and/or without permission to use their records were excluded. Charts were reviewed for maternal and infant characteristics and outcomes. Postnatal depression was identified from a positive screen, referral for mood disorder, antidepressant medication increase, suicidality, or provider diagnosis from delivery to 12 months postpartum. RESULTS: Ninety-one women with pregnancy >23 weeks after surgery and available data were reviewed. The average body mass index at time of surgery was 47±8.6 kg/m2 (N=88) and at time of pregnancy 32±6.6 kg/m2 (N=89). The average age at surgery was 29±4.1 years and at delivery 33±4.4 years. Roux-en-Y gastric bypass was the most common surgery (N=70, 77%). Pregnancy outcomes included: 14% preterm deliveries (<37 weeks, N=13), 67% vaginal deliveries (N=61), no stillbirths, and 97% singleton deliveries (N=88). Mean singleton birthweight was 3225 grams (±471, N=86). Postnatal depression was noted in 38% of women (N=35), which is significantly higher than that for obese women in general (13-18%) when a 1-sample proportion test is conducted for comparison (38%vs18%, p <0.0001). CONCLUSION: Postnatal depression may be increased in women with a history of bariatric surgery. Further investigation is needed, but particular care should be taken to screen and diagnose these high-risk women.
Perinatal Outcome of Fetal Umbilical Vein Varix: A Multicenter Cohort Study [29P]
Novoa, Victoria Arruga Novoa y, Tonni, Gabriele , Prefumo, Federico , Prefumo, Federico , Ruano, Rodrigo

Mayo Clinic

Obstetrics & Gynecology | April 27, 2018 | Volume: 131 | Issue: 1 | Pages: 181S-181S

10.1097/01.aog.0000533203.36122.98 Get It

INTRODUCTION: Umbilical vein varix (UVV) is a focal dilation of the fetal umbilical vein. Clinical significance is not clearly established but it has been associated with adverse outcomes. This study investigates the clinical outcomes of UVV diagnosed during pregnancy. METHODS: We performed a multicenter retrospective (USA, Chile, Italy and Brazil) study by reviewing 19 fetuses diagnosed with UVV between 2012 and 2017. We investigated gestational age at diagnosis and at delivery, UVV maximum diameter, fetal gender, associated anatomical anomalies, intrauterine growth restriction, fetal demise, type of delivery, birth weight, Apgar scores. RESULTS: UVV was diagnosed at 26.4+/- 4.4 weeks of gestation. Maximum diameter of the defect at diagnosis typically was 13.1+/- 5mm. The majority of fetuses were male (n=12, 63%). Growth restriction was diagnosed in 26% (n=5) of the fetuses. Seventeen (89%) infants survived. Fetal demise occurred in 2 (11%) patients; one was associated with structural anomalies, and the other fetus did not have any other associated anomaly. Vaginal delivery was performed in 10 (53%) patients; median weight at birth was 2870 g (270-4960 g). Median Apgar scores were 8 and 9 on 1st and 5th minutes consecutively (ranging from 0 to 10). Genetic and anatomical anomalies were present in 21% (n=4) of the fetuses and included: karyotype 47,XY+13, cleft lip and palate, cerebellar hypoplasia, aortic hypoplasia, cardiomegaly, Blake's pouch cyst, ambiguous genitalia, campomelic dysplasia with SOX9 mutation. CONCLUSION: UVV is a rare congenital condition that is usually associated with low frequency of other structural/genetic anomalies and with good prognosis. ACKNOWLEDGEMENTS: Waldo Sepulveda, Edward Araujo Junior, Mari Charisse Trinidad, and Heron Werner
Intuitive Surgical Inc. Payments to Ob/Gyns Compared to Other Specialties: Analysis from 2014 Open Payments Database [4D]
Guha, Paulami, Espinal, Mariana, Dinh, Tri, DeStephano, Christopher C.

Mayo Clinic

Obstetrics & Gynecology | April 27, 2018 | Volume: 131 | Issue: 1 | Pages: 42S-42S

10.1097/01.aog.0000532983.55418.f9 Get It

INTRODUCTION: Study Objective: To determine the payments made to Obstetricians and Gynecologists (OBGYNs) compared to other surgical specialties by the makers of the Da Vinci robot-Intuitive Surgical, Inc. in 2014. METHODS: Design: Retrospective cross-sectional study (Canadian Task force classification- II-3). Setting: Payments to OBGYNs in the United States compared to the total Intuitive Surgical payment amount in each state as analyzed from Centers for Medicare & Medicaid Services (CMS)’ Open Payments website. Subjects: General OBGYNs, OBGYN subspecialists (Gynecologic Oncology, Reproductive Endocrinology, Female Pelvic Medicine and Reconstructive Surgery, Gynecology), and providers in other specialties nationwide. Interventions: Compare Intuitive Surgical Inc. payments to OBGYNs versus other surgical specialties as analyzed from publicly available CMS Open Payments database. RESULTS: A total of 50 states received money from Intuitive Surgical Inc. in 2014. Payments to general OBGYNs totaled $5,061,439, OBGYN subspecialties received $1,591,556, and other surgical specialties that use the Da Vinci platform received $33,011,657. Total payments per state can be represented in a map diagram. The state of Texas got the highest amount. Payments to OBGYNs divided by total payments in each state can be depicted in a similar fashion, Wyoming state had the highest value. CONCLUSION: OBGYNs received a significant proportion of funding from Intuitive Surgical Inc. as compared to other surgical specialties in 2014. We recommend that OBGYNs update or declare any conflicts when required.
Adderall and Pregnancy: Neonatal Outcomes Following Prenatal Prescription Mixed Amphetamine Exposure [36C]
Rose, Sherrill, Borowski, Kristi, Hathcock, Matthew , White, Wendy , Rivera‐Chiauzzi, Enid Y.

Mayo Clinic

Obstetrics & Gynecology | April 27, 2018 | Volume: 131 | Issue: 1 | Pages: 39S-40S

10.1097/01.aog.0000532976.17300.b9 Get It

INTRODUCTION: Increasing numbers of pregnant women are being treated for ADHD. The safety of ADHD medications in pregnancy have not been well studied, although studies suggest that methylphenidate use may lower birthweight compare to unexposed newborns. Our primary outcome was to evaluate if birthweight was lower among infants of women utilizing Adderall in our academic institution. METHODS: Maternal and infant pairs exposed to Adderall between January 2005 and December 2015 was identified in EMR based on active medication list during pregnancy. Patients were matched 2:1 with unexposed controls of similar age, gestational age at delivery, parity, infant sex and date of delivery. All charts were reviewed for known causes of IUGR or low birthweight. Statistical analysis of infant birthweight was done using generalized estimating equation blocking on matching. Medical histories were analyzed using Chi-Square test or Fishers exact test as appropriate. RESULTS: We identified 53 exposed pairs. The difference in mean birthweight for exposed vs unexposed infants was 26.9g which is not statistically or clinically significant (95% CI, P-value: (-141, 195), 0.75). A statistically significant difference was noted for exposed vs unexposed mothers for comorbid psychiatric illness and history of substance abuse (p = <0.0001). CONCLUSION: As Adderall use increases among childbearing women, understanding the risk to infants is crucial. With a limited sample size, our study suggests no significant difference in birthweight, which is a concern for women requiring medication in pregnancy. Women using Adderall may have higher rates of comorbid psychiatric disorders and substance use and may benefit from early screening.
One Way Video Interviewing As A Method to Augment the Residency Application [5C]
Hopkins, Matthew R. , Occhino, John A. , Weaver, Amy L. , Turner, Norman S. , Breitkopf, Daniel M. , Camp, Christopher L.

Mayo Clinic

Obstetrics & Gynecology | April 27, 2018 | Volume: 131 | Issue: 1 | Pages: 31S-31S

10.1097/01.aog.0000532945.63042.6b Get It

INTRODUCTION: Despite the increase in residency applications, little change in the information available for review prior to a face-to-face interview has occurred. Asynchronous or one way video interviews (OWVI) may offer a way to collect additional data on applicants. Our objective was to assess the feasibility and acceptability of OWVI and to correlate OWVI performance with in-person interview scores. METHODS: Characteristics of successful residents were identified and OWVI questions were developed using medical student volunteers. Candidates who presented for in-person interviews during the 2016-17 season for OB/GYN (n= 45) and Orthopedic Surgery (n=98) were invited to participate in OWVI with 3 questions and a maximum of 3 minutes per question. Videos were reviewed and scored independently by 2 reviewers from the respective departments using a standardized 5-point scale. RESULTS: Forty-six (47%) Orthopedic and eleven (24%) OB/GYN applicants completed OWVI. The interviewer’s scores of OWVI were within one point of one another 84% of the time. High OWVI scores were correlated with higher in-person interview scores (r=0.26) and higher rank list placement (r=0.33). Sixty-two percent of the applicants were satisfied with the OWVI process. Most respondents wanted additional OWVI questions that would allow them to explain why they wanted to apply to a particular program. CONCLUSION: Asynchronous interviews enabled reviewers to differentiate applicants and their scores correlated with rank list placement and in person interview scores. The process was viewed by participants as a way to humanize their application and this may have potential to help screen applicants for residency.
Frequency and Acceptability of Adverse Events After Anterior Cervical Discectomy and Fusion
Wilson, Jefferson R. , Schroeder, Gregory D. , Booth, Madison, Lucasti, Christopher , Fehlings, Michael G. , Nassr, Ahmad, Sciubba, Daniel M. , Ching, Alex, Smith, Justin S. , Shaffrey, Christopher I. , Singh, Kern , Darden, Bruce V., Daffner, Scott D. , Ludwig, Steven C. , Wang, Jeffrey , Lehman, Ronald A. , Hilibrand, Alan S. , Yoon, Tim , Grauer, Jonathan N. , Dailey, Andrew T. , Steinmetz, Michael P. , Ahmad, Nassr, Fehlings, Michael G , Radcliff, Kris E. , Vaccaro, Alexander R. , Arnold, Paul M. , Cheng, Ivan , Ghogawala, Zoher , Buchowski, Jacob M. , Brodke, Darrel Scott , Harrop, James Shields

Mayo Clinic

Clinical Spine Surgery: A Spine Publication | April 27, 2018 | Volume: 31 | Issue: 5 | Pages: E270-E277

10.1097/bsd.0000000000000645 | PMID 29708891 Get It

Purpose: Anterior cervical discectomy and fusion has a low but well-established profile of adverse events. The goal of this study was to gauge surgeon opinion regarding the frequency and acceptability of these events. Methods: A 2-page survey was distributed to attendees at the 2015 Cervical Spine Research Society (CSRS) meeting. Respondents were asked to categorize 18 anterior cervical discectomy and fusion–related adverse events as either: “common and acceptable,” “uncommon and acceptable,” “uncommon and sometimes acceptable,” or “uncommon and unacceptable.” Results were compiled to generate the relative frequency of these responses for each complication. Responses for each complication event were also compared between respondents based on practice location (US vs. non-US), primary specialty (orthopedics vs. neurosurgery) and years in practice. Results: Of 150 surveys distributed, 115 responses were received (76.7% response rate), with the majority of respondents found to be US-based (71.3%) orthopedic surgeons (82.6%). Wrong level surgery, esophageal injury, retained drain, and spinal cord injury were considered by most to be unacceptable and uncommon complications. Dysphagia and adjacent segment disease occurred most often, but were deemed acceptable complications. Although surgeon experience and primary specialty had little impact on responses, practice location was found to significantly influence responses for 12 of 18 complications, with non-US surgeons found to categorize events more toward the uncommon and unacceptable end of the spectrum as compared with US surgeons. Conclusions: These results serve to aid communication and transparency within the field of spine surgery, and will help to inform future quality improvement and best practice initiatives.
Stereotactic radiosurgery for trigeminal pain secondary to recurrent malignant skull base tumors
Phan, Jack , Pollard, Courtney , Brown, Paul D. , Guha‐Thakurta, Nandita , Garden, Adam S. , Fuller, Clifton D. , Frank, Steven J. , Gunn, G. Brandon , Morrison, William H. , Ho, Jennifer , Li, Jing , Ghia, Amol J. , Yang, James N., Luo, Dershan , Wang, He C., Su, Shirley Y. , Raza, Shaan M. , Gidley, Paul W. , Hanna, Ehab Y., Rosenthal, David I. , Hanna, Ehab Y. , DeMonte, Franco , Phan, Jack , Su, Shirley Y , Fuller, Clifton David

Mayo Clinic

Journal of Neurosurgery | April 27, 2018 | Volume: 130 | Issue: 3 | Pages: 812-821

10.3171/2017.11.jns172084 | PMID 29701557 Get It

OBJECTIVEThe objective of this study was to assess outcomes after Gamma Knife radiosurgery (GKRS) re-irradiation for palliation of patients with trigeminal pain secondary to recurrent malignant skull base tumors.METHODSFrom 2009 to 2016, 26 patients who had previously undergone radiation treatment to the head and neck received GKRS for palliation of trigeminal neuropathic pain secondary to recurrence of malignant skull base tumors. Twenty-two patients received single-fraction GKRS to a median dose of 17 Gy (range 15–20 Gy) prescribed to the 50% isodose line (range 43%–55%). Four patients received fractionated Gamma Knife Extend therapy to a median dose of 24 Gy in 3 fractions (range 21–27 Gy) prescribed to the 50% isodose line (range 45%–50%). Those with at least a 3-month follow-up were assessed for symptom palliation. Self-reported pain was evaluated by the numeric rating scale (NRS) and MD Anderson Symptom Inventory–Head and Neck (MDASI-HN) pain score. Frequency of as-needed (PRN) analgesic use and opioid requirement were also assessed. Baseline opioid dose was reported as a fentanyl-equivalent dose (FED) and PRN for breakthrough pain use as oral morphine-equivalent dose (OMED). The chi-square and Student t-tests were used to determine differences before and after GKRS.RESULTSSeven patients (29%) were excluded due to local disease progression. Two experienced progression at the first follow-up, and 5 had local recurrence from disease outside the GKRS volume. Nineteen patients were assessed for symptom palliation with a median follow-up duration of 10.4 months (range 3.0–34.4 months). At 3 months after GKRS, the NRS scores (n = 19) decreased from 4.65 ± 3.45 to 1.47 ± 2.11 (p < 0.001); MDASI-HN pain scores (n = 13) decreased from 5.02 ± 1.68 to 2.02 ± 1.54 (p < 0.01); scheduled FED (n = 19) decreased from 62.4 ± 102.1 to 27.9 ± 45.5 mcg/hr (p < 0.01); PRN OMED (n = 19) decreased from 43.9 ± 77.5 to 10.9 ± 20.8 mg/day (p = 0.02); and frequency of any PRN analgesic use (n = 19) decreased from 0.49 ± 0.55 to 1.33 ± 0.90 per day (p = 0.08). At 6 months after GKRS, 9 (56%) of 16 patients reported being pain free (NRS score 0), with 6 (67%) of the 9 being both pain free and not requiring analgesic medications. One patient treated early in our experience developed a temporary increase in trigeminal pain 3–4 days after GKRS requiring hospitalization. All subsequently treated patients were given a single dose of intravenous steroids immediately after GKRS followed by a 2–3-week oral steroid taper. No further cases of increased or new pain after treatment were observed after this intervention.CONCLUSIONSGKRS for palliation of trigeminal pain secondary to recurrent malignant skull base tumors demonstrated a significant decrease in patient-reported pain and opioid requirement. Additional patients and a longer follow-up duration are needed to assess durability of symptom relief and local control.
Ventral Herniorrhaphy with Reference to a New Technic for Selected Cases
Mayo, Charles W.

Mayo Clinic

Military Medicine | April 27, 2018 | Volume: 129 | Issue: 3 | Pages: 205-210

10.1093/milmed/129.3.205 Get It

Quantifying Rome symptoms for diagnosis of the irritable bowel syndrome
Almazar, Ann E., Locke, G. Richard, Larson, Joseph J. , Atkinson, Elizabeth J. , Saito, Yuri A. , Saito, Y A , Chang, Jennifer Y. , Talley, Nicholas J.

Mayo Clinic

Neurogastroenterology & Motility | April 27, 2018 | Volume: 30 | Issue: 9 | Pages: No page available

10.1111/nmo.13356 | PMID 29701271 Get It

AbstractBackgroundIrritable bowel syndrome (IBS) is a common functional gastrointestinal disorder, diagnosed on symptom‐based criteria. Many have reported discrepancies between formal Rome criteria and diagnoses made in clinical practice. The aim of the study was to explore whether a quantitative version of the Rome criteria would better represent a clinical diagnosis of IBS than the current dichotomous criteria for symptom measure.MethodsAs part of a large, case‐control study, participants completed a validated bowel disease questionnaire. Rome criteria were analyzed based on 15 individual symptoms. Penalized logistic regression model with stepwise selection was used to identify significant symptoms of IBS which were independently associated with case‐control status.Key ResultsIn cases with a clinical diagnosis of IBS, 347 (70%) met Rome criteria for IBS. Increasing number of Rome symptoms were found related to the odds of being diagnosed with IBS. Nearly half of the Rome‐negative case group experienced infrequent symptoms suggesting milder disease. Five of 15 Rome symptoms were associated with predicting case‐control status in the final model, with 96% correctly classified among Rome‐positive cases, 76% for Rome‐negative cases, and 91% for controls.Conclusions and InferencesIrritable bowel syndrome appears to be a spectrum disorder. Quantifying individual symptoms of Rome criteria has greater utility than the current application in representing the degree of IBS affectedness and appears to better reflect a clinical diagnosis of IBS applied by physicians. The use of a quantitative diagnostic Rome “score” may be helpful in clinical practice and research studies to better reflect the degree an individual is affected with IBS.